NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy - PubMed
5 hours ago
- #MRD
- #CLL
- #NGS
- Next-generation sequencing (NGS)-based measurable residual disease (MRD) was assessed in 17 patients with chronic lymphocytic leukemia (CLL) in remission after FCR therapy.
- The median follow-up time was 15.7 years post-treatment.
- Persistent MRD was identified in 13 out of 17 patients (76%), despite long-term progression-free survival.